Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae

International Journal of Antimicrobial Agents

Volumn 26, Issue 1, 2005, Pages 81-84

  Saravolatz, Louis ^a   Manzor, Odette ^a   Pawlak, Joan ^a   Belian, Bradley ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolones; Gemifloxacin; In vitro; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; STREPTOCOCCUS PNEUMONIAE;

EID: 20744440982     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.03.004     Document Type: Article

References (14)

1. M. Takahata, J. Mitsuyama, and Y. Yamashiro In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone Antimicrob Agents Chemother 43 1999 1077 1084
2. V.J. Heaton, J.E. Ambler, and L.M. Fisher Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro Antimicrob Agents Chemother 44 2000 3112 3117
3. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4. 4th ed. Wayne, PA: NCCLS; 1997.
4. G.E. Stein Pharmacokinetics and pharmacodynamics of newer fluoroquinolones Clin Infect Dis 23 Suppl 1 1996 S19 S24
5. T. Bergan Pharmacokinetics of the fluoroquinolones V.T. Andriole The quinolones 2nd ed. 1998 Academic Press San Diego, CA 143 182
6. H.C. Neu The quinolones: prospects V.T. Andriole The quinolones 1988 Academic Press Ltd London, UK 235 254
7. V.T. Andriole The quinolones: prospects V.T. Andriole The quinolones 2nd ed. 1998 Academic Press Ltd London, UK 417 429
8. Zhanel GG, Laing N, Karlowsky J, Hoban D. In vitro characterization of moxifloxacin and comparator fluoroquinolone (FQ)-induced killing of multiple drug-resistant Streptococcus pneumoniae by simulating clinically achievable areas under the curve (AUC). In: Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1998 [Abstract A24].
9. S.L. Preston, G.L. Drusano, and A.L. Berman Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials JAMA 279 1998 125 129
10. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1993 1073 1081
11. K. Drlica Refining the fluoroquinolones ASM News 65 1999 410 415
12. X. Zhao, C. Xu, and K. Drlica DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance Proc Natl Acad Sci USA 94 1997 13991 13996
13. H. Lode, T.M. File Jr., and L.A. Mandell Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy Clin Ther 24 2002 1915 1936
14. Wilson R, Langan C, Ball P, Bateman K. Pypstra R; Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97:242-249.